Redstart Labs invested in Genoscope, a precision oncology diagnostics company developing Saliscope, a saliva-based companion diagnostic test for head and neck cancers. First investment in March 2026.
MAR 2026
Genoscope develops Saliscope, a saliva-based, non-invasive companion diagnostic for head and neck cancer
Genoscope develops Saliscope, a saliva-based, non-invasive companion diagnostic for head and neck cancer. The assay analyzes extracellular-vesicle RNA biomarkers using qRT-PCR and AI-based models to predict treatment response, stratify disease risk, and estimate relapse risk, supporting personalized treatment decisions and monitoring.